𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma

✍ Scribed by Anders Thylén; Anders Hjerpe; Gunnar Martensson

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
91 KB
Volume
92
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of gemcitabine in patie
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
✍ Jan P. van Meerbeeck; Paul Baas; Channa Debruyne; Harry J. Groen; Chris Manegold 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## BACKGROUND. Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted method with which to investigate new therapies in malignant mesothelioma. The European Organization for Research and Treatment of Cancer-Lung Cancer Coo

The sensitivity of hyaluronan analysis o
The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods
✍ Gunnar Martensson; Anders Thylen; Ulla Lindqvist; Anders Hjerpe 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB 👁 1 views

## Background: Hyaluronan may be used as a marker for malignant mesothelioma, thus indicating its mesodermal origin. ## Methods: The sensitivity as a diagnostic test of three different methods for hyaluronan analyses of pleural fluid was examined in patients with biopsy-verified malignant pleural

Cisplatin in combination with irinotecan
Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma : A pilot phase II clinical trial and pharmacokinetic profile
✍ Takashi Nakano; A. Philippe Chahinian; Miho Shinjo; Naoki Togawa; Atsushi Tonomu 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 2 views

The purpose of this study was to assess the efficacy and toxicity of a combination of cisplatin and irinotecan (CPT-11) in the treatment of patients with malignant pleural mesothelioma and to characterize the pharmacokinetic profiles of CPT-11 and its active metabolite, 7-ethyl-10-hydroxycamptotheci